April 18, 2019

TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis

Regimens under clinical development include treatment options for drug-resistant forms of TB
March 20, 2019

Statement on Building a Tuberculosis Free World: The Lancet Commission on Tuberculosis

This is an important moment to take stock of the milestones achieved in the fight against TB and to spur policymakers and funders to commit the necessary resources to end TB.
February 5, 2019

Compound Studied in TB to be Evaluated in the Treatment of Leishmaniasis

Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis
January 18, 2019

Played Red Dead Redemption 2? Here’s what you should know about TB

Whether it’s 1899 or 2019, TB is a serious disease that poses a significant challenge to global health
January 15, 2019

Jan Lundberg Joins TB Alliance Board of Directors

Lundberg has more than 20 years of experience in global R&D management, including the approval of 20+ new medicines
December 11, 2018

Schrödinger and TB Alliance Announce Collaboration to Accelerate Tuberculosis Drug Discovery

Partnership merges Schrödinger’s advanced modeling capabilities with TB Alliance’s expertise in tuberculosis biology to accelerate the development of next-generation treatments
December 4, 2018

Global TB Research Funding Continues to Fall Short

Statement on TAG Report on TB Research Funding Trends
November 28, 2018

TB Alliance Receives GHTC Partnership Award for Development of Child-Friendly TB Medicines

Fixed dose combination medicines now available across 85 countries and set to reach first 800,000 children